Regeneron Ventures Invests in Cell Therapy Company ArsenalBio
Gunderson Dettmer represented client Regeneron Ventures in participating in the $325 million Series C financing of Arsenal Biosciences (ArsenalBio), a clinical stage programmable cell therapy company focused on engineering advanced CAR T-cell therapies for solid tumors. ArsenalBio is aiming to build the industry’s largest DNA library of potential therapeutic enhancing integrated circuits, incorporating logic gating for improved tumor targeting and synthetic features. The new capital will be used to advance ArsenalBio’s lead programs through development as the company continues to build its pipeline of therapeutic candidates and to drive further innovation in developing tools and processes for identifying new candidate cell therapies.
In the announcement of the transaction, ArsenalBio co-founder, CEO and chairman Ken Drazan, M.D. said, “Our initial clinical trials and preclinical studies have shown the promise of our T cell engineering approach and have given us the confidence to broaden the application of our technology to address additional cancer types. This new investment enables us to continue our development roadmap, scale up our manufacturing capabilities, and invest in new avenues for innovation in T cell medicine.”
The Gunderson Dettmer deal team was led by Jeff Engerman and included Tim Kulis.
